Oxime Ether Compounds for Selective S1P1 Agonism
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for S1P1 agonists that are selective over S1P3 to avoid undesirable cardiovascular effects such as bradycardia and hypertension associated with non-selective S1P receptor modulation, which are critical for treating autoimmune and vascular diseases effectively without adverse side effects.
Innovation Solution
Development of substituted oxime ether compounds that act as selective S1P1 agonists, providing pharmaceutical compositions and methods for their use in treating autoimmune and vascular diseases, with improved stability, bioavailability, and therapeutic index.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-selective S1P receptor modulation is used to achieve immunosuppression and prevent transplant rejection, then therapeutic efficacy is improved, but cardiovascular side effects such as bradycardia and hypertension occur
Solution Approach 1:
The patent applies local quality by designing compounds with specific molecular structures (Formula I with defined substituents R1-R6, X, Y, L1, L2) that confer selective affinity for S1P1 receptor over S1P3 receptor. This structural differentiation enables the drug to act locally on specific receptor subtypes, achieving immunosuppressive effects while avoiding cardiovascular side effects associated with S1P3 activation.
Solution Approach 2:
The patent employs parameter changes by modifying molecular parameters (substituent groups, stereochemistry, bond types) of the oxime ether compounds to optimize receptor selectivity. By varying parameters such as the nature of R1-R6 groups and the configuration of chiral centers, the compounds achieve enhanced S1P1 selectivity while maintaining therapeutic efficacy, thereby resolving the contradiction between effectiveness and safety.
2Object-affected harmful factors
If selective S1P1 agonists are developed to avoid cardiovascular side effects, then safety is improved, but the complexity of drug design and development increases
Solution Approach 1:
The patent applies segmentation by dividing the molecular structure into distinct functional segments (core oxime ether structure with separable substituent groups R1-R6). This modular approach allows systematic optimization of each segment for S1P1 selectivity while simplifying the overall design process. The segmented structure enables independent modification of pharmacophore elements without redesigning the entire molecule.
Solution Approach 2:
The patent employs universality by creating a platform compound (Formula I) that can achieve multiple therapeutic goals through systematic substitution. The core structure serves universal functions of S1P1 receptor binding, while variable substituents provide tunable selectivity and pharmacokinetic properties. This multi-functional platform reduces design complexity by reusing the core scaffold across different therapeutic indications.
Data Source
AI summary
Disclosed are compounds of Formula (I): (I) or a salt thereof, wherein: X is CH or N; Y is CH or N; R1 is —OH or —OP(O)(OH)2; L is —CR3═N—O—CRaRa— or CRaR—O—N═CR3; L2 is a bond, —C(O)—, or S(O)2—; and R2, R3, Ra, m, and n are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.